2. Signaling Pathways
  3. MAPK/ERK Pathway
  4. MEK
  5. MEK Isoform

MEK

 

MEK Related Products (40):

Cat. No. Product Name Effect Purity
  • HY-10254
    Mirdametinib
    		Inhibitor 99.95%
    Mirdametinib (PD0325901) is an orally active, selective and non-ATP-competitive MEK inhibitor with an IC50 of 0.33 nM.
  • HY-50706
    Selumetinib
    		Inhibitor 99.87%
    Selumetinib (AZD6244) is selective, non-ATP-competitive oral MEK1/2 inhibitor, with an IC50 of 14 nM for MEK1.
  • HY-15202
    Binimetinib
    		Inhibitor 99.50%
    Binimetinib (MEK162) is an oral and selective MEK1/2 inhibitor.
  • HY-B0185
    Lidocaine
    		Inhibitor 99.96%
    Lidocaine (Lignocaine) inhibits sodium channels involving complex voltage and using dependence.
  • HY-18652
    Avutometinib
    		Inhibitor 98.99%
    Avutometinib (Ro 5126766) is a first-in-class dual MEK/RAF inhibitor that allosterically inhibits BRAFV600E, CRAF, MEK, and BRAF (IC50: 8.2, 56, 160 nM, and 190 nM, respectively).
  • HY-108635
    C16-PAF
    		Activator 99.48%
    C16-PAF (PAF (C16)), a phospholipid mediator, is a platelet-activating factor and ligand for PAF G-protein-coupled receptor (PAFR).
  • HY-B0185A
    Lidocaine hydrochloride
    		Inhibitor 99.81%
    Lidocaine hydrochloride (Lignocaine hydrochloride) inhibits sodium channels involving complex voltage and using dependence.
  • HY-19700
    trans-Zeatin
    		Inhibitor 99.83%
    trans-Zeatin is a plant cytokinin, which plays an important role in cell growth, differentiation, and division; trans-Zeatin also inhibits UV-induced MEK/ERK activation.
  • HY-13449
    TAK-733
    		Inhibitor 99.48%
    TAK-733 is a potent and selective MEK allosteric site inhibitor with an IC50 of 3.2 nM.
  • HY-50706A
    Selumetinib sulfate
    		Inhibitor 99.59%
    Selumetinib (AZD6244) is selective, non-ATP-competitive oral MEK1/2 inhibitor, with an IC50 of 14 nM for MEK1.
  • HY-139558
    Zapnometinib
    		Inhibitor 99.63%
    Zapnometinib (PD0184264), an active metabolite of CI-1040, is a MEK inhibitor, with an IC50 of 5.7 nM.
  • HY-13078
    Cobimetinib racemate
    		Inhibitor 99.71%
    Cobimetinib racemate (GDC-0973 racemate; XL518 racemate) is the racemate of Cobimetinib.
  • HY-12202
    MEK inhibitor
    		Inhibitor 98.55%
    MEK inhibitor is a potent MEK inhibitor with antitumor potency.
  • HY-10174
    PD184161
    		Inhibitor 99.38%
    PD184161 is an orally active MEK inhibitor.
  • HY-10216
    Refametinib (R enantiomer)
    		Inhibitor
    Refametinib R enantiomer is a MEK inhibitor extracted from patent WO2007014011A2, compound 1022, has an EC50 of 2.0-15 nM.
  • HY-19700S
    trans-Zeatin-d5
    		Inhibitor ≥99.0%
  • HY-148507
    GSK1790627
    		Inhibitor
    GSK1790627 is the N-deacetylated metabolite of Trametinib (HY-10999).
  • HY-13079
    Cobimetinib (R-enantiomer)
    		Inhibitor
    Cobimetinib R-enantiomer is the less active R-enantiomer of Cobimetinib.
  • HY-10254G
    Mirdametinib (GMP)
    		Inhibitor
    Mirdametinib (PD0325901) (GMP) is Mirdametinib (HY-10254) produced by using GMP guidelines.
  • HY-111368
    EBI-1051
    		Inhibitor
    EBI-1051 is a highly potent and orally efficacious MEK inhibitor with an IC50 of 3.9 nM.